“duchenne-muscular-dystrophy” Archives

in
Entry Author Date Location
Bio Roundup: Duchenne Race, Warren v. Gottlieb, A $599 Genome & More 07/05/19 National
Vertex Pharma Shells Out $420M to Move Into Muscular Dystrophy 06/07/19 Boston
Stoke Therapeutics Preps IPO to Bring Dravet Syndrome Drug to Clinic 05/24/19 Boston
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More 05/17/19 National
How an Ohio Kids’ Hospital Quietly Became Ground Zero for Gene Therapy 04/15/19 National
Pfizer Bolsters Gene Therapy Position with $51M Vivet Deal 03/20/19 New York
After AGTC Deal Flops, Biogen Bets $800M on Gene Therapy Rival Nightstar 03/04/19 Boston
Sarepta Touts More Gene Therapy Data, Snaps Up Myonexus For $165M 02/27/19 Boston
Roche Bets $4.8B on Spark Therapeutics and the Future of Gene Therapy 02/25/19 National
Passage Bio Gets $116M As Wilson, Yamada Team Up On Gene Therapy Again 02/14/19 National
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More 02/08/19 National
With Its First Human Data, Solid Slips in Duchenne Gene Therapy Race 02/07/19 Boston
Bio Roundup: 2019 Trials, Pilgrim Price Chat, Pre-Xmas Sales & More 12/21/18 National
15 for ’19: Key Clinical Data to Watch for Next Year (Part 1) 12/17/18 National
Bio Roundup: Nobel Prizes, Duchenne Steps, Guardant’s IPO & More 10/05/18 National
Sarepta Touts New Data and a “Signal” With Duchenne Gene Therapy 10/03/18 Boston
Bio Roundup: Amarin’s Stunner, Lung Cancer News, Data Dumps & More 09/28/18 National
Europe Advisory Panel Rejects Sarepta’s Duchenne Drug Once Again 09/21/18 Boston
Working with Patients and a Fresh $80M, Fulcrum Eyes a 2019 IPO 09/05/18 Boston
Bio Roundup: Pfizer’s Rare Results, U.K.’s CAR-T No, IPO Go-Go & More 08/31/18 National
Fresh Off GSK Deal, Gene Therapy Startup Orchard Bags Another $150M 08/13/18 Boston
Bio Roundup: An Alzheimer’s Head-Scratcher, OUTBio, GSK & Gilead Shakeups   07/27/18 National
PTC Dives Into Gene Therapy with $50M Agilis Biotherapeutics Deal 07/19/18 New York
Bio Roundup: Big Bucks For Calico, Data Dumps & The IPO Wave Rolls On 06/29/18 National
Summit Therapeutics Ditches Duchenne Drug In Wake of Phase 2 Failure 06/27/18 Boston
Sarepta’s Data Are First in Rush for Duchenne Gene Therapy 06/19/18 Boston
As Sarepta Preps Data, FDA Lifts Hold on Solid’s Duchenne Gene Therapy 06/18/18 Boston
Bio Roundup: Wrapping ASCO, Dreaming IPO, Rebooting Axovant & More 06/08/18 National
Life Sci Veteran Garabedian Talks Up Biotech Accelerator in Texas 04/23/18 Texas
Bio Roundup: DIY Biohacking, PCSK9 Data, Solid Setback & More 03/16/18 National
Page 1 of 7 next page »